Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the non-small-cell lung cancer drug market in China will reach $640 million in 2011. According to the new Emerging Markets report entitled Non-Small-Cell Lung Cancer in China, the emergence of novel monoclonal antibodies – most notably Genentech/Roche’s Avastin and ImClone/Merck KGaA’s Erbitux – will drive growth. Avastin will be the market leader in China by 2011. Deeper market penetration of recently available small-molecule epidermal growth factor receptor (EGFR) inhibitors (AstraZeneca’s Iressa and Genentech/Roche’s Tarceva) will also add to the growth.